Michael Cola

Michael Cola served as Chief Executive Officer and as a member of the Board of Directors at Avalo Therapeutics, Inc and its predecessors from 2013 to February 2022. Michael has served as president of specialty pharmaceuticals at Shire Plc, a global specialty pharmaceutical company he first joined in 2005 as executive vice-president of global therapeutic business units and portfolio management. Previously, Michael also served as a growth capital provider and president of the life sciences group for Safeguard Scientifics, Inc., where he served as chairman and chief executive officer of Clarient, Inc., and chairman of Laureate Pharma, Inc. In addition, Michael has held senior positions in product development and commercialization at AstraMerck and AstraZeneca.

Michael also serves on the board of Sage Therapeutics, Purdue Pharmaceuticals, as well as the chairman of the board of directors at Phathom Pharmaceuticals. He is the former chairman for the board of governors of the Boys & Girls Clubs of Philadelphia. Michael received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University.